+78.5%
IREN vs MRNA
-41.8%
+120.3%
-95.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.8% | +0.7% | -4.6% | -3.9% |
| 7D | +4.8% | -8.2% | +13.0% | +6.0% |
| 30D | +9.8% | +125.6% | -115.8% | -17.1% |
| 3M | -15.3% | +197.1% | -212.4% | -43.2% |
| 6M | +14.5% | +148.5% | -134.0% | -17.9% |
| YTD | +15.5% | +363.3% | -347.7% | -34.0% |
| 1Y | +29.8% | +462.0% | -432.2% | -32.6% |
| 3Y | +834.5% | +26.9% | +807.6% | +661.8% |
| All | +78.5% | -41.8% | +120.3% | +70.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling